• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

窦状隙内皮细胞中COX-1衍生的前列腺素调节肝硬化大鼠肝脏的肝血管张力。

Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers.

作者信息

Graupera Mariona, March Sandra, Engel Pablo, Rodés Juan, Bosch Jaume, García-Pagán Joan-Carles

机构信息

Hepatic Hemodynamic Laboratory, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain.

出版信息

Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G763-70. doi: 10.1152/ajpgi.00300.2004. Epub 2004 Nov 18.

DOI:10.1152/ajpgi.00300.2004
PMID:15550559
Abstract

CCl(4) cirrhotic rat liver exhibits a hyperresponse to the alpha(1)-adrenergic agonist methoxamine (Mtx) that is associated with enhanced thromboxane A(2) (TXA(2)) production and is abrogated by indomethacin. To further elucidate the molecular mechanisms involved in the hyperresponse to vasoconstrictors, portal perfusion pressure dose-response curves to Mtx were performed in CCl(4) cirrhotic rats livers after preincubation with vehicle, the cyclooxygenase (COX)-1 selective inhibitor SC-560, and the COX-2 selective inhibitor SC-236. TXA(2) production was determined in samples of the perfusate. COX-1 expression was analyzed and quantified in hepatocytes, Kupffer cells, sinusoidal endothelial cells (SEC), and hepatic stellate cells (HSC) isolated from control and cirrhotic rat livers by double-immunofluorescence staining, with specific markers for each population using flow cytometry or Western blot analysis. COX-1 protein levels were not significantly increased in cirrhotic livers, but COX-2 protein expression was increased. COX-1 inhibition, but not COX-2, significantly attenuated the response to Mtx and prevented the increased production of TXA(2). Cirrhotic livers showed an increased expression of COX-1 in SEC and reduced expression in HSC compared with control livers, whereas COX-1 was similarly distributed in Kupffer cells. Despite abundant hepatic COX-2 expression, the increased response to Mtx of cirrhotic livers is mainly dependent of COX-1. Upregulation of COX-1 in cirrhotic SEC may be responsible for the hyperesponse to Mtx.

摘要

四氯化碳诱导肝硬化大鼠的肝脏对α₁ - 肾上腺素能激动剂甲氧明(Mtx)表现出高反应性,这与血栓素A₂(TXA₂)生成增加有关,且吲哚美辛可消除这种反应。为了进一步阐明对血管收缩剂高反应性所涉及的分子机制,在用溶剂、环氧化酶(COX)-1选择性抑制剂SC - 560和COX - 2选择性抑制剂SC - 236预孵育后,对四氯化碳诱导肝硬化大鼠的肝脏进行了门静脉灌注压力对Mtx的剂量反应曲线实验。测定灌注液样本中的TXA₂生成量。通过双重免疫荧光染色,使用针对每个细胞群体的特异性标志物,利用流式细胞术或蛋白质印迹分析,对从对照和肝硬化大鼠肝脏分离出的肝细胞、库普弗细胞、窦状内皮细胞(SEC)和肝星状细胞(HSC)中的COX - 1表达进行分析和定量。肝硬化肝脏中COX - 1蛋白水平没有显著增加,但COX - 2蛋白表达增加。COX - 1抑制而非COX - 2抑制显著减弱了对Mtx的反应,并阻止了TXA₂生成的增加。与对照肝脏相比,肝硬化肝脏中SEC的COX - 1表达增加,HSC中的表达减少,而COX - 1在库普弗细胞中的分布相似。尽管肝脏中COX - 2表达丰富,但肝硬化肝脏对Mtx的反应增加主要依赖于COX - 1。肝硬化SEC中COX - 1的上调可能是对Mtx高反应性的原因。

相似文献

1
Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers.窦状隙内皮细胞中COX-1衍生的前列腺素调节肝硬化大鼠肝脏的肝血管张力。
Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G763-70. doi: 10.1152/ajpgi.00300.2004. Epub 2004 Nov 18.
2
Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.环氧化酶衍生产物调节肝硬化大鼠肝脏肝内阻力增加的情况。
Hepatology. 2003 Jan;37(1):172-81. doi: 10.1053/jhep.2003.50004.
3
Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers.肝血窦内皮细胞产生的血管收缩性前列腺素增加,会导致肝硬化大鼠肝脏的门静脉灌注压升高。
J Hepatol. 2007 Aug;47(2):220-7. doi: 10.1016/j.jhep.2007.03.014. Epub 2007 Apr 5.
4
Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers.环氧化酶-1抑制可纠正肝硬化大鼠肝脏的内皮功能障碍。
J Hepatol. 2003 Oct;39(4):515-21. doi: 10.1016/s0168-8278(03)00347-7.
5
Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis.反对NADPH氧化酶在肝硬化中调节肝血管张力作用的证据。
Gastroenterology. 2007 Sep;133(3):959-66. doi: 10.1053/j.gastro.2007.06.021. Epub 2007 Jun 20.
6
Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2).正常肝脏和纤维化肝脏中的库普弗细胞激活通过血栓素A2增加门静脉压力。
J Hepatol. 2007 Aug;47(2):228-38. doi: 10.1016/j.jhep.2007.03.019. Epub 2007 Apr 9.
7
Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.枯否细胞耗竭可减轻肥胖型非酒精性脂肪性肝炎-肝硬化大鼠模型中介导甲氧胺刺激门脉灌注压和血栓素 A2 释放的瘦素作用。
Clin Sci (Lond). 2012 Dec;123(12):669-80. doi: 10.1042/CS20110572.
8
Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis.大电导钙激活钾通道调节实验性肝硬化中的血管张力。
Liver Int. 2008 Apr;28(4):566-73. doi: 10.1111/j.1478-3231.2008.01668.x.
9
Role of thromboxane A2 in early BDL-induced portal hypertension.血栓素A2在早期胆管结扎诱导的门静脉高压中的作用。
Am J Physiol Gastrointest Liver Physiol. 2003 Mar;284(3):G453-60. doi: 10.1152/ajpgi.00315.2002. Epub 2002 Nov 13.
10
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.氟比洛芬酯,一种释放一氧化氮的环氧化酶抑制剂,可改善大鼠肝硬化门静脉高压症。
Gastroenterology. 2007 Feb;132(2):709-19. doi: 10.1053/j.gastro.2006.12.041. Epub 2006 Dec 20.

引用本文的文献

1
Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease.探索过氧化物酶体增殖物激活受体与内皮功能障碍在代谢功能障碍相关脂肪性肝病中的作用
Cells. 2024 Dec 12;13(24):2055. doi: 10.3390/cells13242055.
2
Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism.依普利酮,一种盐皮质激素受体抑制剂,可减轻肝硬化相关的肝细胞葡萄糖和脂质代谢变化。
Cell Commun Signal. 2024 Dec 20;22(1):614. doi: 10.1186/s12964-024-01991-2.
3
Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.
通过靶向肝窦内皮细胞优化载他汀递送纳米颗粒治疗慢性肝病
Pharmaceutics. 2023 Oct 14;15(10):2463. doi: 10.3390/pharmaceutics15102463.
4
The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer.慢性肝病中的肝血窦:癌症的最佳环境。
Cancers (Basel). 2021 Nov 15;13(22):5719. doi: 10.3390/cancers13225719.
5
Role of liver sinusoidal endothelial cells in liver diseases.肝窦内皮细胞在肝脏疾病中的作用。
Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):411-431. doi: 10.1038/s41575-020-00411-3. Epub 2021 Feb 15.
6
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.心血管介质、氧化应激和炎症在肝脏疾病及其并发症中的相互作用。
Nat Rev Cardiol. 2021 Feb;18(2):117-135. doi: 10.1038/s41569-020-0433-5. Epub 2020 Sep 30.
7
Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.前列腺素在肝硬化门静脉系统凝血中的病理生理作用。
PLoS One. 2019 Oct 23;14(10):e0222840. doi: 10.1371/journal.pone.0222840. eCollection 2019.
8
Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K/AKT and cGMP signalling pathways.急慢性肝病通过增强蛋白激酶 A、磷脂酰肌醇 3-激酶/蛋白激酶 B 和环鸟苷酸信号通路增强苯肾上腺素诱导的大鼠肠系膜阻力动脉内皮型一氧化氮释放。
Sci Rep. 2019 May 6;9(1):6993. doi: 10.1038/s41598-019-43513-y.
9
Update on the management of gastrointestinal varices.胃肠道静脉曲张管理的最新进展。
World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):1-21. doi: 10.4292/wjgpt.v10.i1.1.
10
The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.选择性盐皮质激素受体拮抗剂依普利酮可预防肝硬化失代偿。
Br J Pharmacol. 2018 Jul;175(14):2956-2967. doi: 10.1111/bph.14341. Epub 2018 Jun 7.